These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

368 related items for PubMed ID: 17162211

  • 21. Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation.
    Mandigers CM, Verdonck LF, Meijerink JP, Dekker AW, Schattenberg AV, Raemaekers JM.
    Bone Marrow Transplant; 2003 Dec; 32(12):1159-63. PubMed ID: 14647270
    [Abstract] [Full Text] [Related]

  • 22. Prevention of relapse using DLI can increase survival following HLA-identical transplantation in patients with advanced-stage acute leukemia: a multi-center study.
    Wang Y, Liu DH, Fan ZP, Sun J, Wu XJ, Ma X, Xu LP, Liu KY, Liu QF, Wu DP, Huang XJ.
    Clin Transplant; 2012 Dec; 26(4):635-43. PubMed ID: 22515260
    [Abstract] [Full Text] [Related]

  • 23. Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease?
    Radujkovic A, Guglielmi C, Bergantini S, Iacobelli S, van Biezen A, Milojkovic D, Gratwohl A, Schattenberg AV, Verdonck LF, Niederwieser DW, de Witte T, Kröger N, Olavarria E, Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1230-6. PubMed ID: 25797175
    [Abstract] [Full Text] [Related]

  • 24. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL.
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [Abstract] [Full Text] [Related]

  • 25. Infusion of CD4+ donor lymphocytes induces the expansion of CD8+ donor T cells with cytolytic activity directed against recipient hematopoietic cells.
    Zorn E, Wang KS, Hochberg EP, Canning C, Alyea EP, Soiffer RJ, Ritz J.
    Clin Cancer Res; 2002 Jul; 8(7):2052-60. PubMed ID: 12114403
    [Abstract] [Full Text] [Related]

  • 26. T-cell depleted peripheral blood stem cell allotransplantation with T-cell add-back for patients with hematological malignancies: effect of chronic GVHD on outcome.
    Montero A, Savani BN, Shenoy A, Read EJ, Carter CS, Leitman SF, Mielke S, Rezvani K, Childs R, Barrett AJ.
    Biol Blood Marrow Transplant; 2006 Dec; 12(12):1318-25. PubMed ID: 17162214
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Selected CD34 blood cell allografts for older patients: low transplant-related mortality, graft failure and acute GvHD.
    Roberts MM, Dyson P, Rawling C, Thorp D, Rawling T, White D, Horvath N, Bardy P, Hui CH, Dart GW, To LB, Hughes TP.
    Cytotherapy; 2003 Dec; 5(6):534-41. PubMed ID: 14660049
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Mixed chimera converted into full donor chimera with powerful graft-versus-leukemia effects but no graft-versus-host disease after non T cell-depleted HLA-mismatched peripheral blood stem cell transplantation.
    Wu BY, Guo KY, Song CY, Yang, Li D.
    Bone Marrow Transplant; 2000 Sep; 26(6):691-3. PubMed ID: 11035376
    [Abstract] [Full Text] [Related]

  • 32. T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation.
    Drobyski WR, Hessner MJ, Klein JP, Kabler-Babbitt C, Vesole DH, Margolis DA, Keever-Taylor CA.
    Blood; 1999 Jul 15; 94(2):434-41. PubMed ID: 10397710
    [Abstract] [Full Text] [Related]

  • 33. Can only partial T-cell depletion of the graft before hematopoietic stem cell transplantation mitigate graft-versus-host disease while preserving a graft-versus-leukemia reaction? A prospective phase II study.
    Chalandon Y, Roosnek E, Mermillod B, Waelchli L, Helg C, Chapuis B.
    Biol Blood Marrow Transplant; 2006 Jan 15; 12(1):102-10. PubMed ID: 16399574
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions.
    Huff CA, Fuchs EJ, Smith BD, Blackford A, Garrett-Mayer E, Brodsky RA, Flinn IW, Ambinder RF, Borrello IM, Matsui WH, Vogelsang GB, Griffin CA, Luznik L, Jones RJ.
    Biol Blood Marrow Transplant; 2006 Apr 15; 12(4):414-21. PubMed ID: 16545725
    [Abstract] [Full Text] [Related]

  • 36. Induction of early post-transplant graft-versus-leukemia effects using intentionally mismatched donor lymphocytes and elimination of alloantigen-primed donor lymphocytes for prevention of graft-versus-host disease.
    Yang I, Weiss L, Abdul-Hai A, Kasir J, Reich S, Slavin S.
    Cancer Res; 2005 Nov 01; 65(21):9735-40. PubMed ID: 16266994
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.